PFRED

PFRED designs antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) for targeted gene silencing and optimization of oligonucleotide sequences.


Key Features:

  • Design parameter evaluation: Evaluates multiple design parameters that influence binding efficiency, resistance to degradation, and overall efficacy of ASOs and siRNAs.
  • Sequence specificity assessment: Assesses sequence specificity of candidate oligonucleotides to inform target selection.
  • Thermodynamic and structural analysis: Analyzes thermodynamic properties and structural considerations that contribute to target binding and activity.
  • Library generation: Generates libraries of siRNA and ASO candidates tailored to specified gene targets.
  • Analysis and visualization: Provides analysis and visualization of designed ASO and siRNA candidates for comparison and selection.
  • Algorithmic optimization: Integrates computational algorithms to optimize oligonucleotide sequences based on multiple design parameters.

Scientific Applications:

  • Gene silencing: Enables design of siRNAs and ASOs to downregulate gene expression by targeting mRNA transcripts.
  • Functional genomics: Supports functional genomics studies via targeted knockdown of genes.
  • Therapeutic oligonucleotide development: Aids development and optimization of therapeutic ASOs and siRNAs.
  • Target validation and gene function exploration: Facilitates exploration of gene function in various biological contexts through designed oligonucleotides.

Methodology:

Computational algorithms consider sequence specificity, thermodynamic properties, and structural considerations to optimize oligonucleotide sequences.

Topics

Details

License:
MIT
Programming Languages:
Shell, Ruby, Java
Added:
1/18/2021
Last Updated:
1/23/2021

Operations

Publications

Sciabola S, Xi H, Cruz D, Cao Q, Lawrence C, Zhang T, Rotstein S, Hughes JD, Caffrey DR, Stanton R. PFRED: A computational platform for siRNA and antisense oligonucleotides design. Unknown Journal. 2020. doi:10.1101/2020.08.25.265983.

Downloads

Links